Glenn Schulman, PharmD, MS, BCPS, BCACP BCGP, BCIDP

In this high-risk population, strategies for minimizing viral exposure during a pandemic are being considered with oncology treatment options.

Current cancer research focuses heavily on adjunct immunotherapy in combination with traditional chemotherapy.

Numerous therapeutic options are available for acute myeloid leukemia, but more research is needed to determine how best to use them.

Patients with relapsed/refractory leukemia and lymphomas generally have a grim prognosis, which has paved the way for immunotherapy treatments.

Early diagnosis, surgery while cancer is confined to kidney are key, but pharmacological agents are used for Stage IV.

Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.

Patients with relapsed or refractory lymphomas may benefit from CAR-NK cell immunotherapy and Have fewer adverse events.

There Is Room for Improvement in Treating Malignancies Caused by Infectious Agents, Especially Considering the Cost Differential

Cyclin-Dependent Kinase 4/6 Inhibitors, Margetuximab, Trastuzumab Deruxtecan, and Tyrosine Kinase Inhibitors Have Shown Promising Results

For some patients, stereotactic body radiation therapy may provide an enhanced quality of life, better efficacy, and reduced adverse effects.

Some patients are hesitant to use this class of drugs because of the stigma of potential addiction.